Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of trastuzumab + docetaxel + oxaliplatin in HER2-positive metastatic breast cancer
2006-000413-37Phase 2Terminated
- Sponsor
- Azienda Unità Sanitaria Locale 12 di Viareggio
- Start
- Jun 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, docetaxel and oxaliplatin in breast cancer, sponsored by Azienda Unità Sanitaria Locale 12 di Viareggio. Primary endpoints: Overall response rate, Clinical benefit and 1 more. Started Jun 2006; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-000413-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000413-37.